TickerFacts.

Avalo Therapeutics, Inc. (AVTX): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Older than the company's other figures. The latest Gross Profit is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$640.0K
Year ended 2023-12-31
-29.9%
5-year compound annual growth
$14.62M2018-12-31: $3.77M2021-12-31: $3.91M2022-12-31: $14.62M2023-12-31: $640.0K$640.0K
2018-12-31 Gross Profit (USD) 2023-12-31
Period endedGross ProfitChange YoYSource filing
2023-12-31$640.0K-95.6%2025-03-20, From 2023-01-01
2022-12-31$14.62M+274.1%2024-03-29, From 2022-01-01
2021-12-31$3.91Mn/a2023-03-29, From 2021-01-01
No annual figure between 2018-12-31 and 2021-12-31.
2018-12-31$3.77Mn/a2020-03-11, From 2018-01-01